Autologous Bone Marrow Stem Cell Transplantation for Osteonecrosis in Sickle Cell Disease
Autologous Bone Marrow Stem Cell Transplantation for Osteonecrosis in Sickle Cell Disease
The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow
 stem cells in sickle cell disease patients with osteonecrosis
The aim of this study is to evaluate autologous bone marrow stem cells transplantation as a
 safe and potentially beneficial treatment for sickle cell disease patients with
 osteonecrosis.
Inclusion Criteria:

 -  Stable sickle cell disease patients

 -  FICAT classification of osteonecrosis, inclusive of Stage II.

 -  Diagnosis will be based on X-Ray and magnetic resonance imaging (MRI).

 -  No infection in affected bones at the time of surgery.

 -  Patient competent to give informed consent.

 -  Scoring at least 20 points on the pain and daily life activities questionnaire.

 Exclusion Criteria:

 -  FICAT stage III or more

 -  Patients with a history of corticosteroids or on active therapy

 -  Bone infection at the limb affected by necrosis

 -  Recurrent painful crises,

 -  Immunosuppressive drug therapy,

 -  Pregnancy,

 -  Presence of neoplastic disease or any other clinical concurrent condition other than
 sickle cell disease that predisposed them to the development of osteonecrosis of the
 femoral head